Case fatality of bleeding and recurrent venous thromboembolism during, initial therapy with direct oral anticoagulants: a systematic review.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Thrombosis Research

• Publication date

  2014-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.thromres.2014.07.001PMID 25047174
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.

  2013cited by this paper
• Extended use of dabigatran, warfarin, or placebo in venous thromboembolism.

  2013cited by this paper
• [Oral Rivaroxaban for the treatment of symptomatic pulmonary embolism].

  2013influential reference
• Efficacy and safety outcomes of oral anticoagulants and antiplatelet drugs in the secondary prevention of venous thromboembolism: systematic review and network meta-analysis

  2013cited by this paper
• Oral apixaban for the treatment of acute venous thromboembolism.

  2013influential reference
• Apixaban for extended treatment of venous thromboembolism.

  2013cited by this paper
• New oral anticoagulants: which one should my patient use?

  2012cited by this paper
• Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.

  2012cited by this paper
• Diagnosis of DVT: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

  2012cited by this paper
• Treatment of venous thromboembolism – effects of different therapeutic strategies on bleeding and recurrence rates and considerations for future anticoagulant management

  2012cited by this paper
• Oral rivaroxaban for symptomatic venous thromboembolism.

  2011influential reference
• The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials

  2011cited by this paper
• Systematic Review: Case-Fatality Rates of Recurrent Venous Thromboembolism and Major Bleeding Events Among Patients Treated for Venous Thromboembolism

  2010cited by this paper
• Oral rivaroxaban for symptomatic venous thromboembolism.

  2010cited by this paper
• Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients

  2010cited by this paper
• Dabigatran versus warfarin in the treatment of acute venous thromboembolism.

  2009cited by this paper
• The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration

  2009cited by this paper
• Prediction rules in cervical spine injury

  2009cited by this paper
• Practice Guidelines (8th Edition) of Chest Physicians Evidence-Based Clinical Thromboembolic Disease: American College Antithrombotic Therapy for Venous

  2008cited by this paper
• The epidemiology of venous thromboembolism in the community.

  2008cited by this paper
• Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

  2008cited by this paper
• Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non‐surgical patients

  2005cited by this paper
• Long-term management of patients after venous thromboembolism.

  2004cited by this paper
• Bmc Medical Research Methodology Open Access Meta-analytic Methods for Pooling Rates When Follow-up Duration Varies: a Case Study

  2004influential reference
• Diagnosis of pulmonary embolism.

  2003cited by this paper
• Essential Medical Statistics

  2003cited by this paper
• The Epidemiology of Venous Thromboembolism

  2003cited by this paper
• Quantifying heterogeneity in a meta‐analysis

  2002cited by this paper
• Epidemiology of Venous Thromboembolism

  2001cited by this paper
• Risk of fatal pulmonary embolism in patients with treated venous thromboembolism.

  1998cited by this paper
• Antithrombotic therapy for venous thromboembolic disease.

  1989cited by this paper
• Meta-analysis in clinical trials.

  1986cited by this paper
• A computer program for testing average partial association in three-way contingency tables (PARCAT).

  1979cited by this paper
• Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis.

  1979influential reference
• The Inverse of the Freeman – Tukey Double Arcsine Transformation

  1978cited by this paper
• Diagnosis of pulmonary embolism.

  1973cited by this paper
• A controlled trial

  1971cited by this paper
• EPIDEMICS OF TYPHOID FEVER.

  1964cited by this paper
• Anticoagulant drugs in the treatment of pulmonary embolism. A controlled trial.

  1960influential reference

• MicroRNAs as potential biomarkers and future therapeutic targets in thrombosis: from molecular mechanisms to clinical implications.

  2026cites this paper
• Continued versus discontinued oral anticoagulant treatment for unprovoked venous thromboembolism: target trial emulation

  2025cites this paper
• Simultaneous quantification of eighteen therapeutic oral anticoagulants, rodenticides, and antiplatelet agents by LC-MS/MS and its application in post-mortem forensic cases.

  2025cites this paper
• Use of ISTH bleeding assessment scale to evaluate therapy-associated bleeding risk in patients undergoing coronary revascularization

  2024cites this paper
• Major hemorrhage and mortality in COVID-19 patients on therapeutic anticoagulation for venous thromboembolism

  2022cites this paper
• Mortality Rate in Upper Gastrointestinal Bleeding Associated with Anti-Thrombotic Therapy Before and During Covid-19 Pandemic

  2022cites this paper
• Deep Venous Thrombosis

  2022cites this paper
• Use of idarucizumab for emergency surgery in patients taking dabigatran

  2022cites this paper
• Cost-Effectiveness Analysis of Direct Oral Anticoagulants Versus Vitamin K Antagonists for Venous Thromboembolism in China

  2021cites this paper
• Bleeding Risk Assessment in Patients with Venous Thromboembolism

  2021cites this paper
• A Meta-Analysis of Case Fatality Rates of Recurrent Venous Thromboembolism and Major Bleeding in Patients with Cancer

  2020cites this paper
• Long-term treatment of venous thromboembolism.

  2020cites this paper
• Outcomes of endovascular venous stenting in patients on direct oral anticoagulants and antiplatelet therapy at a tertiary referral center.

  2020cites this paper
• ETNA-VTE Europe: Benefits and risks of venous thromboembolism treatment using edoxaban in the first 3 months.

  2020cites this paper
• Which patients are at high risk of recurrent venous thromboembolism (deep vein thrombosis and pulmonary embolism)?

  2020cites this paper
• Which patients are at high risk of recurrent venous thromboembolism (deep vein thrombosis and pulmonary embolism)?

  2020cites this paper
• Pharmacokinetic and pharmacodynamic drug monitoring of direct acting oral anticoagulants: Where do we stand?

  2019cites this paper
• Prolonged Anticoagulation Therapy for venous Thromboembolism: Resolved Issuesand Controversial Questions

  2019cites this paper
• High incidence of venous thromboembolism recurrence in patients with sickle cell disease

  2019cites this paper
• American College of Surgeons' Guidelines for the Perioperative Management of Antithrombotic Medication.

  2018cites this paper
• Outpatient management of pulmonary embolism.

  2017cites this paper
• Prevention of thrombosis in antiphospholipid syndrome.

  2016cites this paper
• Reversal agents for use with direct and indirect anticoagulants.

  2016cites this paper
• The use of novel oral anticoagulants in cancer patients with venous thromboembolism.

  2016cites this paper
• Idarucizumab, a Specific Reversal Agent for Dabigatran: Mode of Action, Pharmacokinetics and Pharmacodynamics, and Safety and Efficacy in Phase 1 Subjects.

  2016cites this paper
• Idarucizumab, a specific reversal agent for dabigatran: mode of action, pharmacokinetics and pharmacodynamics, and safety and efficacy in phase 1 subjects.

  2016cites this paper
• Genotype-guided versus standard vitamin K antagonist dosing algorithms in patients initiating anticoagulation

  2015cites this paper
• Anticoagulants oraux directs (AOD) : du retour d’expérience à la sécurisation de la prise en charge médicamenteuse

  2015cites this paper
• Acute phase treatment of VTE: Anticoagulation, including non-vitamin K antagonist oral anticoagulants

  2015influential citation